Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

NCT00974311
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

NCT00006101
View directory record Official record
Conditions
Prostate Cancer
Interventions
eflornithine, Placebo
Drug
Lead sponsor
Thomas E. Ahlering
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 31, 2026, 2:38 AM EDT
Recruiting Phase 2 Interventional

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

NCT07745361
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Interventions
Oral MRT-2359, Apalutamide
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970
View directory record Official record
Conditions
Prostate Cancer
Interventions
celecoxib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
Behavioral · Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 31, 2026, 2:38 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005960
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy
Biological · Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Los Angeles, California • Vero Beach, Florida • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

NCT01923727
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[89Zr]Df-IAB2M
Biological
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 31, 2026, 2:38 AM EDT
Recruiting Not applicable Interventional

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

NCT06826924
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Fasting, Ketone Supplementation
Behavioral · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

NCT04716725
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
68Ga-PSMA-11, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Not listed Not applicable Interventional

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

NCT02524860
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal-Fusion Bx
Device
Lead sponsor
Focal Healthcare Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 31, 2026, 2:38 AM EDT
Withdrawn Not applicable Interventional

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

NCT04399824
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 31, 2026, 2:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

NCT00526591
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, conventional surgery
Drug · Procedure
Lead sponsor
Jorge A. Garcia, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 31, 2026, 2:38 AM EDT
Active, not recruiting Phase 3 Interventional

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

NCT00071968
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Not applicable Interventional

Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer

NCT00900835
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer, Pain, Prostate Cancer
Interventions
educational intervention, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment, standard follow-up care
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 1Phase 2 Interventional

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

NCT05633160
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-BBN, 67Cu-SAR-BBN
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 31, 2026, 2:38 AM EDT
Recruiting No phase listed Observational

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

NCT01441089
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

NCT03910660
View directory record Official record
Conditions
Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
Interventions
BXCL701 plus Pembrolizumab, BXCL701 monotherapy
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Not yet recruiting Phase 2 Interventional

Folate Study in Men With Advanced Prostate Cancer

NCT06536374
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimethoprim Tablets
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 2:38 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

NCT00808418
View directory record Official record
Conditions
Prostate Cancer
Interventions
Elesclomol Sodium, Docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Fountain Valley, California • Rochester, Maryland • Bismarck, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 31, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Efficacy Study of ABR-215050 to Treat Prostate Cancer

NCT00560482
View directory record Official record
Conditions
Prostate Cancer
Interventions
ABR-215050, tasquinimod, Placebo
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
54
States / cities
Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 31, 2026, 2:38 AM EDT